FindTrial
Sign In

A study to compare two usg methods to assess brest tumor response to chemotherapy

To Compare Superb Microvascular Imaging (SMI) with RECIST in Assessing Response to Neoadjuvant Chemotherapy in Females with Breast Cancer: A Longitudinal Observational Study - SMART-BC

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/06/111918
Enrollment
174
Registered
2026-06-04
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50-C50- Malignant neoplasms of breast

Interventions

Intervention1: Nil: Nil

Sponsors

Pratik Chaudhari
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Female patients more than 18 Years age Newly diagnosed breast cancer Planned for NACT Provided informed consent

Exclusion criteria

Exclusion criteria: Pregnant females Bilateral breast cancer. Distant metastasis.

Design outcomes

Primary

MeasureTime frame
Accuracy of SMI in predicting pathological response to neoadjuvant chemotherapy compared with RECIST criteria.Timepoint: T0 at the time of presentation T1 after completion of 4 cycles of NACT (3 months)—

Countries

India

Contacts

Public ContactProf Farhanul Huda

AIIMS RISHIKESH

farhanul1973huda@gmail.com9997533211

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026